Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated Split-virion influenza vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lot 1 |
| 2 | EXPERIMENTAL | Lot 2 |
| 3 | EXPERIMENTAL | Lot 3 |
| 4 | ACTIVE_COMPARATOR | Control |
| Name | Type | Description |
|---|---|---|
| Inactivated Split-virion influenza vaccine | BIOLOGICAL | Vaccine Lot 1 |
Inclusion Criteria : * Aged 18 to 60 years on the day of inclusion. * Informed consent form signed. * Able to attend all scheduled visits and to comply with all trial procedures. * For a woman, inability to bear a child or negative urine pregnancy test at the first visit. Exclusion Criteria : * S...
Inactivated Split-virion influenza vaccine is an investigational vaccine being studied for the prevention of Orthomyxoviridae infection, which includes influenza and myxovirus infection. It is designed to protect against these viral infections and is currently in clinical development.
Sanofi (ticker: SNY) is developing Inactivated Split-virion influenza vaccine. The company is conducting clinical trials to evaluate the vaccine's safety and efficacy in preventing Orthomyxoviridae infection.
Inactivated Split-virion influenza vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed to assess its performance.
Inactivated Split-virion influenza vaccine has one completed Phase 3 trial, NCT00383539, titled "Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults." This randomized, double-blind, active-controlled study enrolled 2,256 healthy adults aged 18 years and older across France, Lithuania, Spain, and the United Kingdom.
Inactivated Split-virion influenza vaccine is a vaccine that contains inactivated, split influenza virus particles. It works by exposing the immune system to these viral components, prompting an immune response that prepares the body to fight off future influenza infections.
Inactivated Split-virion influenza vaccine is an investigational influenza vaccine designed to prevent flu caused by Orthomyxoviridae viruses. It is similar in concept to seasonal flu shots, but it is still in clinical development and not yet commercially available.